Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R.
Peyrin-Biroulet L, et al. Among authors: jahnsen j.
BMC Gastroenterol. 2024 Mar 27;24(1):121. doi: 10.1186/s12876-024-03163-5.
BMC Gastroenterol. 2024.
PMID: 38539103
Free PMC article.